Navigation Links
Finkelstein Thompson LLP Announces Filing of Securities Fraud Class Action Against CellCyte Genetics Corporation
Date:2/5/2008

WASHINGTON, Feb. 5 /PRNewswire-USNewswire/ -- Notice is hereby given that Finkelstein Thompson LLP has filed a Class Action lawsuit in the United State District Court for the Western District of Washington on behalf of a class (the "Class") consisting of all persons or entities who purchased or otherwise acquired the common stock of CellCyte Genetics Corporation ("CellCyte" or the "Company") (OTC Bulletin Board: CCYG.OB) between April 6, 2007 and January 9, 2008 inclusive (the "Class Period").

A copy of the Complaint is available from the court or from Finkelstein Thompson LLP. Please call us toll-free at (877) 337-1050 to discuss this action or to obtain a copy of the Complaint. You may also contact us by email at contact@finkelsteinthompson.com, or visit our website at http://www.finkelsteinthompson.com.

The Complaint alleges that CellCyte misled the investing public throughout the Class Period by publishing false information about the history and experience of the company's chief executive officer Gary A. Reys. Specifically, Plaintiff alleges that CellCyte misrepresented Reys' credentials on the Company's website and in SEC filings, particularly regarding Reys' educational background, his status as a certified public accountant in the state of Washington, and his prior role in the initial public offerings of var2ious pharmaceutical companies.

According to the Complaint, CellCyte made false and misleading statements about Reys to the SEC and potential investors. The truth regarding Reys' credentials began to surface in early January after news media inquiries into Reys' background. Shortly after these inquiries, CellCyte removed numerous claims regarding Reys' credentials from the Company's website.

As a result of Defendant's misrepresentations and omissions, CellCyte's stock traded at inflated levels during the Class Period. Once the truth behind Reys was revealed, CellCyte shares plunged 55% in unusually heavy trading on January 8 and 9. The stock fell as low as $2.15 on January 9, 2008, down from a high of $7.02 just days before.

Plaintiff seeks to recover damages on behalf of Class members and is represented by Finkelstein Thompson LLP. Finkelstein Thompson LLP has spent almost three decades delivering outstanding representation to institutional and individual clients in connection with securities and other finance-related litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, in the past decade, the firm has served leadership roles in cases that have recovered over $1 billion for investors and consumers.

If you are a member of the class, you may request that the Court appoint you as lead plaintiff by no later than March 14, 2008. A lead plaintiff is a class member appointed by the Court to direct the litigation on behalf of the class. Although a class member need not be appointed as a lead plaintiff to receive a proportionate share of any proceeds of the litigation, lead plaintiffs make important decisions that could affect the prosecution of the class claims, including decisions concerning settlement. The securities laws create a rebuttable presumption that the plaintiff with the largest financial interest in the litigation is the most adequate to serve as a lead plaintiff. Any member of the purported class may move the Court to serve as lead plaintiff through the counsel of their choice and returning a form to counsel or communicating with counsel is not necessary to participate in any recovery.

If you are a CellCyte shareholder and wish to discuss the case, please contact our Washington, D.C. office toll-free at (877) 337-1050, or by email at contact@finkelsteinthompson.com.


'/>"/>
SOURCE Finkelstein Thompson LLP
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Finkelstein Thompson LLP Announces GPC Biotech AG Investigation
2. MHA Announces: Tommy Thompson to be Keynote Speaker at The MHA 5th Annual Business Summit
3. SpectraScience Appoints the Honorable Tommy Thompson to its Board of Directors
4. DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results
5. Physicians Reference Laboratory Announces New Diagnostic for Womens Health
6. CardioTech Announces Conference Call on February 12 at 2:30 PM Eastern for Third Quarter of Fiscal 2008
7. NeoStem Announces NY State License for Adult Stem Cell Collection
8. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
9. China-Biotics, Inc. Announces Rescheduling of Conference Call to Discuss Third Quarter 2008 Results
10. Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
11. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... GA (PRWEB) , ... April 29, 2016 , ... ... of medical devices used in spinal surgical procedures, today announced the completion of ... enhanced value proposition for current and future customers and partners. Kohlberg & ...
(Date:4/29/2016)... ... , ... Intelligent Implant Systems announced today that the two-level components for the ... United States. These components expand the capabilities of the system and allow Revolution™ ... October of 2015, the company has seen significant sales growth in 1Q 2016, and ...
(Date:4/28/2016)... ... April 28, 2016 , ... Connecticut Innovations ... growing companies, today announced the launch of VentureClash , a $5 million ... , “VentureClash looks to attract the best early-stage companies here in Connecticut, ...
(Date:4/27/2016)... Boston (PRWEB) , ... April 27, 2016 , ... ... driven by semantic web technology, today announced that it has been named to The ... life sciences, financial services and other markets, Cambridge Semantics serves the needs of end ...
Breaking Biology Technology:
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
(Date:3/21/2016)... , March 22, 2016 ... with passcodes for superior security   ... leading provider of secure digital communications services, today announced ... technology and offer enterprise customers, particularly those in the ... recognition and voice authentication within a mobile app, alongside, ...
Breaking Biology News(10 mins):